Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 5/20 | 0.42 |
| ▸ | CNR2 | P34972 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ACLY | P53396 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2540756 | 0.96 | NR3C1 (0.40) | CNR1CNR2LMNATP53MAPT | |
| SCHEMBL2535074 | 0.95 | EGFR (0.40) | CNR1CNR2LMNATP53MAPT | |
| SCHEMBL2539725 | 0.94 | CNR1 (0.44) | CNR1CNR2LMNATP53MAPT | |
| SCHEMBL2539084 | 0.93 | CNR1 (0.43) | CNR1CNR2TP53MAPTEGFR | |
| SCHEMBL2540535 | 0.93 | L3MBTL1 (0.46) | CNR1CNR2LMNATP53EGFR | |
| SCHEMBL2539073 | 0.92 | CNR1 (0.47) | CNR1CNR2ADRA1AADRA1BDRD2 | |
| SCHEMBL2540594 | 0.92 | CNR1 (0.47) | CNR1CNR2ADRA1AADRA1BDRD2 | |
| SCHEMBL2539070 | 0.92 | CNR1 (0.47) | CNR1CNR2ADRA1AADRA1BDRD2 | |
| SCHEMBL2538846 | 0.92 | CNR1 (0.40) | CNR1CNR2LMNATP53MAPT | |
| SCHEMBL2543421 | 0.91 | LMNA (0.41) | CNR1CNR2LMNATP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044053-B2 | Sulfonamide substituted pyrazoline compounds, their preparation and use as CB1 modulators | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2011-10-25 | — | — | US | claimed |
| EP-2079701-A1 | SULFONAMIDE SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS CB1 MODULATORS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-07-22 | — | — | EP | claimed |
| WO-2008043544-A1 | SULFONAMIDE SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS CB1 MODULATORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-04-17 | — | — | WO | claimed |
| US-8044053-B2 | Sulfonamide substituted pyrazoline compounds, their preparation and use as CB1 modulators | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2011-10-25 | — | — | US | disclosed |
| US-8044053-B2 | Sulfonamide substituted pyrazoline compounds, their preparation and use as CB1 modulators | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2011-10-25 | — | — | US | disclosed |
| US-8044053-B2 | Sulfonamide substituted pyrazoline compounds, their preparation and use as CB1 modulators | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2011-10-25 | — | — | US | disclosed |
| US-20100184772-A1 | SULFONAMIDE SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS CB1 MODULATORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-07-22 | — | — | US | disclosed |
| US-20100184772-A1 | SULFONAMIDE SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS CB1 MODULATORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-07-22 | — | — | US | disclosed |
| US-20100184772-A1 | SULFONAMIDE SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS CB1 MODULATORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184772-A1 | SULFONAMIDE SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS CB1 MODULATORS | CNR2, CNR1, FAAH | CNR1 2/4885CNR2 1/4885LMNA 3203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.